Literature DB >> 9639376

Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.

C J Ferro1, J C Spratt, W G Haynes, D J Webb.   

Abstract

BACKGROUND: Neutral endopeptidase (NEP) degrades vasoactive peptides, including the natriuretic peptides, angiotensin II, and endothelin-1. Systemic inhibition of NEP does not consistently lower blood pressure, even though it increases natriuretic peptide concentrations and causes natriuresis and diuresis. We therefore investigated the direct effects of local inhibition of NEP on forearm resistance vessel tone. METHODS AND
RESULTS: Four separate studies were performed, each with 90-minute drug infusions. In the first study, 10 healthy subjects received a brachial artery infusion of the NEP inhibitor candoxatrilat (125 nmol/min), which caused a slowly progressive forearm vasoconstriction (12+/-2%; P=0.001). In a second two-phase study, 6 healthy subjects received, 4 hours after enalapril (20 mg) or placebo, an intra-arterial infusion of the NEP inhibitor thiorphan (30 nmol/min). Thiorphan caused similar degrees of local forearm vasoconstriction (P=0.6) after pretreatment with both placebo (13+/-1%, P=0.006) and enalapril (17+/-6%, P=0.05). In a third three-phase study, 8 healthy subjects received intra-arterial thiorphan (30 nmol/min), the endothelin ETA antagonist BQ-123 (100 nmol/min), and both combined. Thiorphan caused local forearm vasoconstriction (13+/-1%, P=0.0001); BQ-123 caused local vasodilatation (33+/-3%, P=0.0001). Combined thiorphan and BQ-123 caused vasodilatation (32+/-1%, P=0.0001) similar to BQ-123 alone (P=0.98). In a fourth study, 6 hypertensive patients (blood pressure >160/100 mm Hg) received intra-arterial thiorphan (30 nmol/min). Thiorphan caused a slowly progressive forearm vasoconstriction (10+/-2%, P=0.0001).
CONCLUSIONS: Inhibition of local NEP causes vasoconstriction in forearm resistance vessels of both healthy volunteers and patients with hypertension. The lack of effect of ACE inhibition on the vasoconstriction produced by thiorphan and its absence during concomitant ETA receptor blockade suggest that it is mediated by endothelin-1 and not angiotensin II. These findings may help to explain the failure of systemic NEP inhibition to lower blood pressure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9639376     DOI: 10.1161/01.cir.97.23.2323

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  43 in total

Review 1.  Secretory pathways in endothelin synthesis.

Authors:  F D Russell; A P Davenport
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 2.  Crosstalk between endothelin and nitric oxide in the control of vascular tone.

Authors:  M Lavallée; M Takamura; R Parent; E Thorin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

3.  Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.

Authors:  Lodi C W Roksnoer; Richard van Veghel; René de Vries; Ingrid M Garrelds; Usha M Bhaggoe; Edith C H Friesema; Frank P J Leijten; Marko Poglitsch; Oliver Domenig; Marian C Clahsen-van Groningen; Ewout J Hoorn; A H Jan Danser; Wendy W Batenburg
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

Review 4.  Dual-acting angiotensin receptor-neprilysin inhibition.

Authors:  Julian Segura; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

Review 5.  Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.

Authors:  Paul M McKie; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2015-02

6.  The Mechanism of Action of LCZ696.

Authors:  Juan Tamargo Menendez
Journal:  Card Fail Rev       Date:  2016-05

Review 7.  Vasopeptidase inhibition and endothelial function in hypertension.

Authors:  L V d'Uscio; T F Lüscher
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 8.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

Review 9.  Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.

Authors:  Stuart B Prenner; Sanjiv J Shah; Clyde W Yancy
Journal:  Curr Atheroscler Rep       Date:  2016-08       Impact factor: 5.113

Review 10.  Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

Authors:  Scott A Hubers; Nancy J Brown
Journal:  Circulation       Date:  2016-03-15       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.